Federated Hermes (NYSE:FHI) Q4 2025 Earnings call January 30, 2026 09:00 AM ET Speaker7Greetings. Welcome to the FHI Q4 2025 analyst call and webcast. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. Please note this conference is being recorded. I will now turn the conference over to your host, Ray Hanley, President ...

Standex International (NYSE:SXI) Q2 2026 Earnings call January 30, 2026 08:30 AM ET Company ParticipantsAdemir Sarcevic - CFOChristopher Howe - Head of Investor RelationsDavid Dunbar - CEOConference Call ParticipantsChris Moore - AnalystGary Prestopino - AnalystMatt Koranda - AnalystMike Shlisky - AnalystRoss Sparenblek - AnalystOperatorGood morning, ladies and gentlemen, and welcome to Standex International's Fiscal Second Quarter 2026 Financial Results Conference Call. At this time, all lines are in a lis ...

Standex International (NYSE:SXI) Q2 2026 Earnings call January 30, 2026 08:30 AM ET Company ParticipantsAdemir Sarcevic - CFOChristopher Howe - Head of Investor RelationsDavid Dunbar - CEOConference Call ParticipantsChris Moore - AnalystGary Prestopino - AnalystMatt Koranda - AnalystMike Shlisky - AnalystRoss Sparenblek - AnalystOperatorGood morning, ladies and gentlemen, and welcome to Standex International's Fiscal Second Quarter 2026 Financial Results Conference Call. At this time, all lines are in a lis ...

Financial Data and Key Metrics Changes - The company reported net income available to common shareholders of $19.6 million or $0.96 per diluted share for Q4 2025, and $73.4 million or $3.61 per diluted share for the full year [4] - Return on average assets was 120 basis points for the year, while return on average equity was 12.38%, both exceeding annual guidance [4] - The efficiency ratio for the year was 58% [4] Business Line Data and Key Metrics Changes - Total loans increased by 1.5% in Q4 and 4% year-over-year to $4.66 billion, driven by strong demand in commercial lending [6] - Commercial business loans were down modestly on a linked-quarter basis but up 11% year-over-year, while commercial mortgage loans increased by 4% from the previous quarter and 6.5% year-over-year [6] - Residential lending grew modestly, up 1% during both the 3 and 12 months ended December 31, 2025 [7] - Consumer indirect loans decreased by 3.7% in Q4 and 4.5% for the year to $807 million [8] Market Data and Key Metrics Changes - Year-end total deposits were $5.21 billion, down 2.8% from September 30, driven by seasonal public deposit outflows [9] - Deposits were up 2% year-over-year despite the ongoing wind down of the banking-as-a-service line of business [9] Company Strategy and Development Direction - The company is focused on organic credit discipline growth, prudent expense management, and building a strong capital position to deliver long-term value to shareholders [22] - The company aims to drive sustainable growth through its community bank and wealth management firm, leveraging its size and market position as competitive advantages [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of Upstate New York markets, particularly with the recent $100 billion investment by Micron Technology [7] - The company anticipates higher performance for full year 2026, targeting a return on average assets of at least 122 basis points and an efficiency ratio below 58% [12] - Management expects to maintain a focus on profitable spreads and favorable credit mix, with a targeted annual loan growth of about 5% driven by commercial lending [14] Other Important Information - The company completed an $80 million subordinated debt offering with a fixed rate of 6.5%, which is favorable compared to previous issuances [5] - The company reported a BBB- rating from Kroll with a stable outlook, reflecting improved profitability and capital position [6] Q&A Session Summary Question: Margin outlook and expected cadence - Management indicated that margins were impacted by the sub debt raise and expect margins to expand incrementally throughout the year [26] Question: Loan growth and indirect auto portfolio management - Management confirmed intentional management of the indirect auto portfolio and expressed confidence in commercial lending growth opportunities [30] Question: Share buyback strategy - Management noted that share buybacks remain an attractive capital allocation option, with a focus on maintaining Common Equity Tier 1 above 11% [34] Question: ROA improvement potential - Management highlighted that accelerated asset originations could positively impact ROA, but profitability remains a priority over growth [40] Question: Deposit targets and initiatives - Management emphasized a focus on core deposit acquisition and successful treasury management offerings to drive deposit growth [43]

Colgate-Palmolive Company (NYSE:CL) Q4 2025 Earnings call January 30, 2026 08:30 AM ET Company ParticipantsAndrea Teixeira - Executive DirectorBonnie Herzog - Managing DirectorDara Mohsenian - Managing Director in US Beverage and Household Products SectorsFilippo Falorni - Director in Equity ResearchJohn Faucher - Chief Investor Relations Officer and EVP in M&AKaumil Gajrawala - Managing Director in Beverage, Household Products, and HALO StrategyKevin Grundy - Managing DirectorLauren Lieberman - Managing Di ...

Financial Data and Key Metrics Changes - The company reported net income available to common shareholders of $19.6 million or $0.96 per diluted share for Q4 2025, and $73.4 million or $3.61 per diluted share for the full year [4] - Return on average assets was 120 basis points for the year, while return on average equity was 12.38%, both exceeding annual guidance [4] - The efficiency ratio for the year was 58% [4] Business Line Data and Key Metrics Changes - Total loans increased by 1.5% in Q4 and 4% year-over-year to $4.66 billion, driven by strong demand in commercial lending [6] - Commercial business loans were down modestly on a linked-quarter basis but up 11% year-over-year [7] - Residential lending grew modestly, up 1% during both the 3 and 12 months ended December 31, 2025 [8] - Consumer indirect loans decreased by 3.7% in Q4 and 4.5% for the year to $807 million [9] Market Data and Key Metrics Changes - Year-end total deposits were $5.21 billion, down 2.8% from September 30, driven by seasonal public deposit outflows [10] - Deposits were up 2% year-over-year despite the ongoing wind down of the banking-as-a-service line of business [10] - The company expects low single-digit deposit growth year-over-year amid a highly competitive landscape [17] Company Strategy and Development Direction - The company is focused on organic growth, credit discipline, and maintaining a strong capital position to deliver long-term value to shareholders [24] - The strategic plan emphasizes deep relationships, prudent expense management, and balancing investments in people and technology [24] - The company aims to drive sustainable growth through its community bank and wealth management firm [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the durability and growth potential of Upstate New York markets, particularly with the recent investment by Micron Technology [8] - The company anticipates stronger residential production in 2026, supported by new producers building their clientele [9] - Management expects a targeted return on average assets of at least 122 basis points and return on average equity exceeding 11.9% for 2026 [13] Other Important Information - The company approved a more than 3% increase to its quarterly dividend and a new share repurchase plan in 2025 [5] - The company completed an $80 million subordinated debt offering with a favorable fixed rate of 6.5% [5] - The company reported a BBB- rating from Kroll with a stable outlook, reflecting improved profitability and capital position [6] Q&A Session Summary Question: Margin outlook and expected cadence - Management indicated that margins were impacted by the sub debt raise and expect incremental expansion throughout the year [28] Question: Loan growth outlook and indirect auto portfolio - Management confirmed intentional management of the indirect auto portfolio and expressed confidence in commercial loan growth opportunities [32] Question: Share buyback strategy - Management stated that share buybacks remain an attractive capital allocation option, with a focus on maintaining Common Equity Tier 1 above 11% [36] Question: ROA improvement potential - Management noted that accelerated asset originations could impact ROA, but they prioritize profitability over growth [41] Question: Deposit growth initiatives - Management emphasized a focus on core deposit acquisition and the success of treasury management offerings in driving commercial deposit growth [44]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved a 14% growth in EPS and a 7% growth for the full year, aligning with mid to high single-digit guidance [9] - The operating ratio improved to 60.1% in Q4, a 250 basis point improvement year-over-year, and 61.7% for the full year, improving 120 basis points compared to 2024 [9][33] - Cash flow generated was $3.3 billion, up 8% driven by cash from operations, with capital spending remaining disciplined [9][37] Business Line Data and Key Metrics Changes - The company saw a 5% year-over-year increase in workload, supported by record-setting grain tonnage from Western Canada [18] - Intermodal revenues increased by 13% internationally and 6% domestically, with strong performance at Vancouver and Prince Rupert [25] - Petroleum and Chemicals segment experienced growth across all areas, particularly a 9% increase in natural gas liquids volumes [26] Market Data and Key Metrics Changes - The company faced continued softness in key markets like forest products and metals, impacted by weak fundamentals and tariffs [25][30] - Tariffs and trade uncertainty negatively impacted full year 2025 revenues by over $350 million [27] - The outlook for 2026 suggests volumes will be flattish compared to 2025, with expectations of continued pressure in forest products and metals [12][30] Company Strategy and Development Direction - The company is focused on disciplined execution, prioritizing levers it can control, and maintaining strong cash flow while returning excess capital to shareholders [11][13] - The management emphasized the importance of operational efficiency and cost control, with a commitment to improving margins as volumes return [14][22] - The company is positioned to leverage its access to North American markets and natural resources, aiming to support customers as trade flows evolve [16][58] Management's Comments on Operating Environment and Future Outlook - The management acknowledged high uncertainty in the economic environment, with muted growth expectations and challenges related to tariffs [12][30] - The company plans to continue focusing on productivity and cost control, with a base case expectation of flat volumes for 2026 [12][39] - Management expressed confidence in the underlying earnings power of the business, despite current headwinds, and highlighted the potential for growth in natural resources and trade diversification [52][77] Other Important Information - The board approved a 3% increase in dividends, marking the 30th consecutive year of dividend growth [37] - A new share buyback program was authorized, allowing the repurchase of up to 24 million common shares [38] Q&A Session Summary Question: Update on incremental revenue target - The company closed with $100 million in incremental revenue for Q4, with a pipeline of another $100 million developing in January [45] Question: Clarification on depreciation and earnings growth - Depreciation variance was due to a favorable study and corrections from past acquisitions; the company is experiencing unique headwinds affecting earnings growth [49][50] Question: Outlook on mix and differentiated growth opportunities - The mix impact for 2026 is expected to be similar to 2025, with opportunities in northern markets and natural resources, particularly in agriculture and energy [56][58] Question: Guidance on volume and earnings shape for 2026 - The first half of 2026 is expected to be softer, with improvement anticipated in the second half, influenced by share buybacks [62] Question: Clarification on free cash flow conversion - The company expects improved free cash flow conversion in 2026, despite a sizable cash tax payment impacting the effective tax rate [80]

Financial Data and Key Metrics Changes - Regeneron reported total revenues of $3.9 billion for Q4 2025, a 3% increase year-over-year, driven by higher collaboration revenue and strong sales growth of Dupixent, EYLEA HD, and Libtayo [40][41] - Diluted net income per share was $11.44, with net income reaching $1.2 billion [40] - The company generated $4.1 billion in free cash flow for 2025 and returned $3.8 billion to shareholders, primarily through share repurchases [44][45] Business Line Data and Key Metrics Changes - Dupixent achieved global net sales of $4.9 billion in Q4 2025, reflecting a 32% year-over-year growth [36] - EYLEA HD net product sales in the U.S. were $506 million in Q4, up 66% year-over-year, while EYLEA 2 mg sales declined 15% sequentially to $577 million [9][34] - Libtayo reported global net sales of $425 million in Q4, a 13% increase year-over-year, with strong demand across all approved indications [37] Market Data and Key Metrics Changes - Dupixent is now the most widely used innovative branded antibody medicine, with over 1.4 million patients globally [7] - EYLEA HD has become a significant part of Regeneron's anti-VEGF franchise, contributing nearly half of total net sales [33] - Libtayo is recognized as the leading immunotherapy for advanced non-melanoma skin cancers, with a strong market position in advanced non-small cell lung cancer [8][37] Company Strategy and Development Direction - Regeneron aims for at least four FDA approvals in 2026, including three for new molecular entities and the EYLEA HD prefilled syringe [11] - The company plans to initiate 18 additional Phase III studies, targeting approximately 35,000 patients over multiple years [13] - Regeneron is focused on advancing its pipeline in oncology, immunology, and ophthalmology, leveraging genetics to guide its R&D strategy [68][70] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about reaching an agreement with U.S. government agencies to reduce drug costs while ensuring patient access to innovative treatments [11] - The company anticipates continued growth in EYLEA HD and Dupixent, with significant opportunities in underpenetrated markets [36][7] - Management highlighted the importance of maintaining a competitive edge through innovative product development and strategic partnerships [70] Other Important Information - Regeneron is committed to helping patients afford their medications, matching a $60 million donation to a fund for retinal disease patients [10] - The company is actively engaging in discussions to address the long-standing imbalance in the distribution of costs for medical innovation [11] Q&A Session Summary Question: Update on Libtayo plus fianlimab readouts - Management indicated that the best estimate for advanced melanoma readout is in the first half of the year, with adjuvant timing also expected in the same timeframe [52] Question: Dupixent IP and future runway - Management refrained from providing additional comments but acknowledged Sanofi's positive outlook on Dupixent's future [55] Question: Frontline metastatic melanoma data and hazard ratio - Management stated that the study is powered to achieve a primary endpoint similar to the current standard of care, with hopes for better outcomes [63] Question: Broader R&D strategy and focus areas - Management emphasized a balanced approach across therapeutic areas, driven by genetics to identify new drug opportunities [70] Question: Development of a new version of Dupixent - Management confirmed ongoing development of a potentially improved version of Dupixent, with plans to move it forward in clinical trials [76]

Regeneron Pharmaceuticals (NasdaqGS:REGN) Q4 2025 Earnings call January 30, 2026 08:30 AM ET Company ParticipantsAkash Tewari - Managing Director and Global Head of Biopharmaceutical ResearchAlexandria Hammond - Director and Head of TherapeuticsChris Raymond - Managing DirectorChristopher Fenimore - EVP and CFODavid Risinger - Senior Managing DirectorGeoff Meacham - Managing DirectorGeorge Yancopoulos - Board Co-Chair, Co-Founder, President, and Chief Scientific OfficerLeonard Schleifer - Board Co-Chair, Co ...

American Express Company (NYSE:AXP) Q4 2025 Earnings call January 30, 2026 08:30 AM ET Company ParticipantsBrian Foran - Managing DirectorChristophe Le Caillec - CFOCraig Maurer - Managing DirectorDon Fandetti - Managing DirectorJeff Adelson - Executive DirectorKartik Ramachandran - Head of Investor RelationsMoshe Orenbuch - Managing DirectorRick Shane - Managing DirectorRyan Nash - Managing Director for Regional Banks and Consumer FinanceSteve Squeri - Chairman and CEOConference Call ParticipantsCris Kenne ...